Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 9051–9100 of 34751
Additionally, on June 7, 2024, the Company appointed Mr. Vineet Jawa to serve as an independent member of the Corporation’s Board of Directors to serve until the next annual meeting of the Corporation or until his respective successor is duly appointed.
On June 11, 2024, Marcus Ryu informed Guidewire Software, Inc. (the “Company”) of his intent to not stand for re-election to the Company’s board of directors (the “Board”) at the Company’s 2024 annual meeting of stockholders.
On June 10, 2024, the Board of Directors of RXO, Inc. (the “Company”) appointed Mr. Troy Cooper as a Class II Director.
Olivier Litzka, Ph.D. informed the Board of his decision to resign from the Board, effective June 13, 2024.
the Board appointed Alexander M. Gold, M.D. as a member of the Board and the Nominating and Corporate Governance Committee of the Board.
Paul H. Pickle and Sylvia Summers Couder no longer serve as directors on the Board of Directors (the "Board") of the Company.
Paul H. Pickle and Sylvia Summers Couder no longer serve as directors on the Board of Directors (the "Board") of the Company.
Robert H. Herz notified Fannie Mae of his resignation from the Fannie Mae Board of Directors, and his resignation was accepted. Mr. Herz’s resignation will be effective June 30, 2024.
On June 12, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Livingston “Tony” Satterthwaite as a member of the Board, effective June 12, 2024.
On June 13, 2024, Mohamad Ali resigned from the Board, effective immediately.
the Board of Directors of the Company (the "Board") appointed Julien Mininberg as a Class II director.
In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024
On June 12, 2024, the Board of Trustees (the “Board”) of PennyMac Mortgage Investment Trust (the “Company”) elected SiSi Pouraghabagher as an independent Class III Trustee.
On June 7, 2024, Radclyffe Roberts also provided notice of his resignation as member of the Board and as a member of the Board’s Compensation Committee (the “Compensation Committee”) as well as a member and chair of the Board’s M&A Committee.
On June 7, 2024, Inchul Chung provided notice of his resignation as a member of the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) and as a member of the Board’s Audit Committee (the “Audit Committee”).
On June 6, 2024, in connection with the IPO, Kwan Sun, James Zhang and Ning Ma were appointed to the board of directors of the Company (the “Board”).
On June 6, 2024, in connection with the IPO, Kwan Sun, James Zhang and Ning Ma were appointed to the board of directors of the Company (the “Board”).
On June 6, 2024, in connection with the IPO, Kwan Sun, James Zhang and Ning Ma were appointed to the board of directors of the Company (the “Board”).
Mark Gerhard, Riaan Hodgson, Robert Foresman, Michael Jesselson and Mickie Rosen were appointed to the board of directors of the Company.
Mark Gerhard, Riaan Hodgson, Robert Foresman, Michael Jesselson and Mickie Rosen were appointed to the board of directors of the Company.
Mark Gerhard, Riaan Hodgson, Robert Foresman, Michael Jesselson and Mickie Rosen were appointed to the board of directors of the Company.
Mark Gerhard, Riaan Hodgson, Robert Foresman, Michael Jesselson and Mickie Rosen were appointed to the board of directors of the Company.
Mark Gerhard, Riaan Hodgson, Robert Foresman, Michael Jesselson and Mickie Rosen were appointed to the board of directors of the Company.
On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.
On May 21, 2024, the Company appointed Yang Huan as a member of the Company’s Board of Directors.
On May 21, 2024, China Foods Holdings, Ltd. (the “Company”) appointed Kong Liqi as a member of the Company’s Board of Directors.
elected James Shannon, M.D., as a Class I director of the Company
On June 12, 2024, Mr. C. Dean Scarborough, a member of the board of directors (the “Board”) of 1st Franklin Financial Corporation, retired from the Board.
Effective June 10, 2024, the Board of Directors (the “Board”) of Tyson Foods, Inc. (the “Company”) increased the size of the Board from fourteen to fifteen directors, and appointed Maria N. Martinez as a member of the Board.
On June 11, 2024, Lisa Cummins notified WiSA Technologies, Inc. (the “Company”) of her decision to resign from the Company’s board of directors (the “Board”), effective June 12, 2024.
On June 12, 2024, the Board, pursuant to its powers under the Company’s bylaws, appointed Kimberly Briskey as a member of the Board to replace Ms. Cummins, effective June 12, 2024.
Effective June 11, 2024, Illumina, Inc., as sole member of GRAIL, LLC (the “Company”), established a board of directors of the Company (the “Board”) and appointed each of Charles Dadswell, Ankur Dhingra and William (Bill) Chase (together, the “Directors”) to the Board.
Effective June 11, 2024, Illumina, Inc., as sole member of GRAIL, LLC (the “Company”), established a board of directors of the Company (the “Board”) and appointed each of Charles Dadswell, Ankur Dhingra and William (Bill) Chase (together, the “Directors”) to the Board.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Upon his appointment as Chief Executive Officer, John C. Santora will join the board as a director.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.
On June 6, 2024, Brett P. Seabert, serving as a Director and Audit Committee Chair on the Board of Directors (the “Board”) of Rocky Mountain Chocolate Factory, Inc. (the “Company”), notified the Board of his intention to resign effective June 6, 2024.
On June 12, 2024, the Company’s Board of Directors appointed Alan J. Sweet as a new director of the Company, effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.